Logo image of MDGS

MEDIGUS LTD - SPON ADR (MDGS) Stock Fundamental Analysis

NASDAQ:MDGS - Nasdaq - US58471G4091 - ADR - Currency: USD

2.36  +0.18 (+8.28%)

After market: 2.6 +0.24 (+10.17%)

Fundamental Rating

2

Taking everything into account, MDGS scores 2 out of 10 in our fundamental rating. MDGS was compared to 187 industry peers in the Health Care Equipment & Supplies industry. MDGS has a bad profitability rating. Also its financial health evaluation is rather negative. MDGS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MDGS had negative earnings in the past year.
In the past year MDGS has reported a negative cash flow from operations.
In the past 5 years MDGS reported 4 times negative net income.
MDGS had a negative operating cash flow in each of the past 5 years.
MDGS Yearly Net Income VS EBIT VS OCF VS FCFMDGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 5M -5M -10M

1.2 Ratios

MDGS has a Return On Assets (-15.49%) which is in line with its industry peers.
MDGS's Return On Equity of -41.78% is in line compared to the rest of the industry. MDGS outperforms 51.28% of its industry peers.
Industry RankSector Rank
ROA -15.49%
ROE -41.78%
ROIC N/A
ROA(3y)-6.62%
ROA(5y)-36.99%
ROE(3y)-13.71%
ROE(5y)-66.82%
ROIC(3y)N/A
ROIC(5y)N/A
MDGS Yearly ROA, ROE, ROICMDGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

1.3 Margins

MDGS has a worse Gross Margin (14.92%) than 81.03% of its industry peers.
MDGS's Gross Margin has declined in the last couple of years.
MDGS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-21.6%
MDGS Yearly Profit, Operating, Gross MarginsMDGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

MDGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MDGS has been reduced compared to 1 year ago.
MDGS has a worse debt/assets ratio than last year.
MDGS Yearly Shares OutstandingMDGS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
MDGS Yearly Total Debt VS Total AssetsMDGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -0.19, we must say that MDGS is in the distress zone and has some risk of bankruptcy.
MDGS has a Altman-Z score of -0.19. This is comparable to the rest of the industry: MDGS outperforms 45.64% of its industry peers.
A Debt/Equity ratio of 0.11 indicates that MDGS is not too dependend on debt financing.
The Debt to Equity ratio of MDGS (0.11) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -0.19
ROIC/WACCN/A
WACC7.41%
MDGS Yearly LT Debt VS Equity VS FCFMDGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M 30M 40M

2.3 Liquidity

MDGS has a Current Ratio of 1.30. This is a normal value and indicates that MDGS is financially healthy and should not expect problems in meeting its short term obligations.
MDGS's Current ratio of 1.30 is on the low side compared to the rest of the industry. MDGS is outperformed by 87.69% of its industry peers.
A Quick Ratio of 1.23 indicates that MDGS should not have too much problems paying its short term obligations.
The Quick ratio of MDGS (1.23) is worse than 75.90% of its industry peers.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.23
MDGS Yearly Current Assets VS Current LiabilitesMDGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

MDGS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -116.00%.
MDGS shows a strong growth in Revenue. In the last year, the Revenue has grown by 158.35%.
The Revenue has been growing by 187.58% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-116%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65%
Revenue 1Y (TTM)158.35%
Revenue growth 3Y598.11%
Revenue growth 5Y187.58%
Sales Q2Q%52.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.58%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25.68%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDGS Yearly Revenue VS EstimatesMDGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
MDGS Yearly EPS VS EstimatesMDGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2020 2021 2022 2023 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MDGS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDGS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDGS Price Earnings VS Forward Price EarningsMDGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGS Per share dataMDGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

MDGS has a Yearly Dividend Yield of 29.82%, which is a nice return.
In the last 3 months the price of MDGS has falen by -30.59%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 1.91, MDGS pays a better dividend. On top of this MDGS pays more dividend than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, MDGS pays a better dividend.
Industry RankSector Rank
Dividend Yield 29.82%

5.2 History

MDGS does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MDGS Yearly Dividends per shareMDGS Yearly Dividends per shareYearly Dividends per share 2022 1 2 3 4

5.3 Sustainability

The earnings of MDGS are negative and hence is the payout ratio. MDGS will probably not be able to sustain this dividend level.
DP-31.57%
EPS Next 2YN/A
EPS Next 3YN/A
MDGS Yearly Income VS Free CF VS DividendMDGS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 0 5M -5M -10M

More info and screens

MEDIGUS LTD - SPON ADR

NASDAQ:MDGS (4/17/2024, 8:12:04 PM)

After market: 2.6 +0.24 (+10.17%)

2.36

+0.18 (+8.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-23 2022-09-23/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change-99.92%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.47M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 29.82%
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP-31.57%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 6.13
EV/EBITDA N/A
EPS(TTM)-6.98
EYN/A
EPS(NY)-4.9
Fwd EYN/A
FCF(TTM)-4.25
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS58.21
BVpS16.77
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.49%
ROE -41.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.92%
FCFM N/A
ROA(3y)-6.62%
ROA(5y)-36.99%
ROE(3y)-13.71%
ROE(5y)-66.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-21.6%
F-Score3
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.17%
Cap/Sales 1.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 1.23
Altman-Z -0.19
F-Score3
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)598.88%
Cap/Depr(5y)379.57%
Cap/Sales(3y)37.08%
Cap/Sales(5y)27.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-116%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65%
EPS Next Y25.58%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)158.35%
Revenue growth 3Y598.11%
Revenue growth 5Y187.58%
Sales Q2Q%52.72%
Revenue Next Year25.68%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.17%
OCF growth 3YN/A
OCF growth 5YN/A